$3080 | SAVE $420 | Single User
$6160 | SAVE $840 | Site License
$9240 | SAVE $1,260 | Enterprise License

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H2 2018
[Report Updated: 20-11-2018]

Published by Global Markets Direct: 20 Nov 2018 | 227555 | In Stock
Related Topics: Cancer , Colorectal Cancer , Human Papillomavirus (HPV) , Lymphoma , Multiple Myeloma , Myeloma , Ophthalmology , Protein

Introduction

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H2 2018

Summary

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. The latest report Serine Protein Kinase ATM - Pipeline Review, H2 2018, outlays comprehensive information on the Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Serine Protein Kinase ATM is a serine/threonine protein kinase. It activates checkpoint signaling upon double strand breaks (DSBs), apoptosis and genotoxic stresses such as ionizing ultraviolet A light (UVA), thereby acting as a DNA damage sensor. It plays a role in replication-dependent histone mRNA degradation. It binds DNA ends. The molecules developed by companies in Phase I, Preclinical and Discovery stages are 3, 2 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology and Ophthalmology which include indications Adenocarcinoma, Colorectal Cancer, Colorectal Tumor, Gastric Cancer, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Herpetic Keratitis, Human Papillomavirus (HPV) Associated Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Solid Tumor and Squamous Cell Carcinoma.

Furthermore, this report also reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)

- The report reviews Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

- The report assesses Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1)Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents
for Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018]

  • Table of Contents

    List of Tables

    List of Figures

    Introduction

    Global Markets Direct Report Coverage

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Overview

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Development

    Products under Development by Stage of Development

    Products under Development by Therapy Area

    Products under Development by Indication

    Products under Development by Companies

    Products under Development by Universities/Institutes

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Therapeutics Assessment

    Assessment by Mechanism of Action

    Assessment by Route of Administration

    Assessment by Molecule Type

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Companies Involved in Therapeutics Development

    AstraZeneca Plc

    InteRNA Technologies BV

    Merck KGaA

    Shuttle Pharmaceuticals Inc

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Drug Profiles

    Antisense RNAi Oligonucleotide to Inhibit ATM for Head And Neck Cancer Squamous Cell Carcinoma - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AZD-0156 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    AZD-1390 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    KU-55933 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    M-3541 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Small Molecule to Inhibit ATM for Colorectal Tumor - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    SP-1161 - Drug Profile

    Product Description

    Mechanism Of Action

    R&D Progress

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Dormant Products

    Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Product Development Milestones

    Featured News & Press Releases

    Apr 18, 2016: AstraZeneca Presents Data On Next-generation Investigational ATM Inhibitor at the AACR 2016 Annual Meeting

    Appendix

    Methodology

    Coverage

    Secondary Research

    Primary Research

    Expert Panel Validation

    Contact Us

    Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

227555 | GMDHC1798TDB

Number of Pages

32

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) - Pipe...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division Protein Kinase 9 or Serine/Threonine Protein Kinase PITALR or CDK9 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2018
Cyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division ...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) - Pipeline Review, H2 ...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2018
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) - Pipeline Review, H2 2...
20 Nov 2018 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) - Pipeline Review, H2 2016
Cyclin Dependent Kinase 6 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE...
23 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DYRK Protein Kinase or Dual specificity YAK1 Related Kinase or HP86 or Protein Kinase Minibrain Homolog or DYRK1A or EC 2.7.12.1) - Pipeline Review, H2 2016
Dual Specificity Tyrosine Phosphorylation Regulated Kinase 1A (Serine/Threonine Kinase MNB or MNB/DY...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein Kinase 7 or TFIIH Basal Transcription Factor Complex Kinase Subunit or Serine/Threonine Protein Kinase 1 or CDK7 or EC 2.7.11.22 or EC 2.7.11.23) - Pipeline Review, H2 2016
Cyclin Dependent Kinase 7 (39 kDa Protein Kinase or CDK Activating Kinase 1 or Cell Division Protein...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or MKNK1 or EC 2.7.11.1) - Pipeline Review, H2 2016
MAP Kinase Interacting Serine/Threonine Protein Kinase 1 (MAP Kinase Signal Integrating Kinase 1 or ...
16 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Catalytic Subunit or Cell Division Protein Kinase 5 or CDK5 or EC 2.7.11.1) - Pipeline Review, H2 2016
Cyclin Dependent Like Kinase 5 (Serine/Threonine Protein Kinase PSSALRE or Tau Protein Kinase II Cat...
09 Nov 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info
SAVE 12% today! Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or EC 2.7.11.1) - Pipeline Review, H2 2016
Glycogen Synthase Kinase 3 Beta (Serine/Threonine Protein Kinase GSK3B or GSK3B or EC 2.7.11.26 or E...
26 Oct 2016 by Global Markets Direct USD $3,080 (normally
USD $3,500)
More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Serine Protein Kinase ATM (Ataxia Telangiectasia Mutated or ATM or EC 2.7.11.1) - Pipeline Review, H2 2018 [Report Updated: 20-11-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...